CITIUS ONCOLOGY INC

For the period ended Sep 30, 2024. Filed Dec 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Dec 27, 2024

CTOR$0.56+2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

2024 · 2023
Cash Flows From Operating Activities:
Net loss	$(21,148,747)		$(12,697,241)
Adjustments to reconcile net loss to net cash provided by operating activities:
Stock-based compensation expense	7,498,817		1,965,500
Deferred income tax expense	576,000		576,000
Changes in operating assets and liabilities:
Inventory	(2,133,871)		-
Prepaid expenses	(1,100,000)		(5,044,713)
Accounts payable	2,422,577		1,196,734
Accrued expenses	(259,071)		(801,754)
Due to related party	14,270,648		14,805,474
Net Cash Provided By Operating Activities	126,353		-
Cash Flows From Investing Activities:
License payment	(5,000,000)		-
Net Cash Used In Investing Activities	(5,000,000)		-
Cash Flows From Financing Activities:
Cash contributed by parent	3,827,944		-
Merger, net	(2,754,296)		-
Proceeds from issuance of note payable to related party	3,800,111		-
Net Cash Provided By Financing Activities	4,873,759		-
Net Change in Cash and Cash Equivalents	112		-
Cash and Cash Equivalents – Beginning of Year	-		-
Cash and Cash Equivalents – End of Year	$112	$	-
Supplemental Disclosures of Cash Flow Information and Non-cash Activities:
IPR&D Milestones included in License Payable	$28,400,000	$	-
Capital Contribution of due to related party by parent	$33,180,961	$	-
Prepaid Manufacturing transferred to Inventory	$6,134,895	$	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.